Key result
Activated prothrombin complex concentrate (aPCC) increased the odds of achieving an INR <1.4 compared to plasma in warfarin-associated hemorrhage (75.8% vs 43.9%; OR 4.3; 95% CI 2.6-7.3; P<0.05).
Why the study?
Does activated prothrombin complex concentrate (aPCC) improve INR reversal compared to plasma in adult patients with warfarin-associated hemorrhage?
Population
276 adult patients with warfarin-associated hemorrhage
Comparison
Activated four-factor prothrombin complex… vs Plasma
Design
Cohort
Follow-up
24 hours
Authors
Loading...
aPCC was associated with superior INR reversal versus plasma; leaves open need for RCTs on clinical outcomes in warfarin hemorrhage.
Cohort (n=276)
No
Does activated prothrombin complex concentrate (aPCC) improve INR reversal compared to plasma in adult patients with warfarin-associated hemorrhage?
Odds Ratio: 4.3 (95% CI 2.6–7.3)
Absolute Event Rate: 75.8% vs 43.9%
p-value: p=<0.05
In patients with warfarin-associated hemorrhage, aPCC is more effective than plasma at rapidly lowering INR to <1.4 without increasing the risk of thromboembolic events.
Rowe et al. (2016) conducted a cohort in Warfarin-associated hemorrhage (n=276). Activated four-factor prothrombin complex concentrate (aPCC) vs. Plasma was evaluated on Achieving an INR of less than 1.4 (OR 4.3, 95% CI 2.6-7.3, p=<0.05). Activated prothrombin complex concentrate (aPCC) increased the odds of achieving an INR <1.4 compared to plasma in warfarin-associated hemorrhage (75.8% vs 43.9%; OR 4.3; 95% CI 2.6-7.3; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: